Statistics on Biotechnology Use  
Results by sector of operation
Company sector. Biotechnology results by main variables and no. of employees. 
Unidades: specified in variables

;Fewer than 250 employees;250 or more employees;Total;
No. of companies carrying out R&D in Biotechnology;1.040;93;1.133;
%Companies according to biotechnology used: Genetic code;32;43;33;
%Companies according to biotechnology used: Functional units;40;51;41;
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;22;41;24;
%Companies according to biotechnology used: Bioprocesses;48;69;50;
%Companies according to biotechnology used: Sub-cellular organisms;5;12;6;
%Companies according to biotechnology used: Bio-computing;24;28;24;
%Companies according to biotechnology used: Nanobiotechnology;13;13;13;
%Companies according to biotechnology used: Other;15;8;14;
Companies in which biotechnology activities are: Main and/or exclusive;581;22;603;
Companies in which biotechnology activities are: A secondary line of business;155;18;173;
Companies in which biotechnology activities are: A tool necessary for production;305;53;357;
%Company by field(s) of ultimate application of biotechnology use: Human Health;45;49;45;
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;19;3;18;
%Company by field(s) of ultimate application of biotechnology use: Food products;30;39;31;
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;23;17;22;
%Company by field(s) of ultimate application of biotechnology use: Environment;13;17;14;
%Company by field(s) of ultimate application of biotechnology use: Industry;13;9;12;
Personnel in R&D in biotechnology (no. of persons);8.124;3.386;11.510;
Personnel in R&D in biotechnology (no. of persons): Researchers;4.552;1.650;6.202;
Personnel in R&D in biotechnology (no. of persons): Technicians and assistants;3.572;1.736;5.308;
Personnel in R&D in biotechnology (no. of persons): women;4.363;2.026;6.389;
Personnel in R&D in biotechnology (no. of persons): (women) Researchers;2.368;935;3.304;
Personnel in R&D in biotechnology (no. of persons): (women) Technicians and assistants;1.995;1.090;3.086;
Personnel in R&D in biotechnology (FTE);5.788,1;2.448,9;8.236,9;
Personnel in R&D in biotechnology (FTE): Researchers;3.364,3;1.231,9;4.596,1;
Personnel in R&D in biotechnology (FTE): Technicians and assistants;2.423,8;1.217;3.640,8;
Personnel in R&D in biotechnology (FTE): women;3.197,5;1.501;4.698,5;
Personnel in R&D in biotechnology (FTE): (women) Researchers;1.803,7;708,8;2.512,5;
Personnel in R&D in biotechnology (FTE): (women) Technicians and assistants;1.393,8;792,2;2.186;
Internal expenditure on R&D (thousands of euros);558.184;211.247;769.431;
1) By nature of the expense: Current expenses;518.032;201.684;719.715;
1.1) Remuneration to researchers;154.555;66.892;221.447;
1.2) Remuneration to technicians and assistants;72.617;50.192;122.809;
1.3) Other current expenses;290.860;84.599;375.459;
2) By nature of the expense: Capital expenses;40.152;9.563;49.715;
2.1) Land and buildings;6.661;2.860;9.521;
2.2) Equipment and instruments;24.465;6.001;30.466;
2.3) Acquisition of specific R&D software;1.157;653;1.810;
2.4) Otros productos de propiedad intelectual específicos para I+D;7.869;49;7.919;
1.1) By origin of the funds: Own funds;385.847;105.066;490.913;
1.2) By origin of the funds: From companies;53.140;29.409;82.548;
1.3) By origin of the funds: Public Administration funds;64.168;32.641;96.809;
1.4) By origin of the funds: From Universities;197;0;197;
1.5) By origin of the funds: From non profit private institutions;588;4.177;4.766;
1.6) By origin of the funds: Foreign funds;54.244;39.954;94.197;
Purchase of R&D services in biotechnology (thousands of euros);68.331;51.951;120.281;
Purchase of R&D services in biotechnology (thousands of euros): In Spain;22.667;46.897;69.564;
Purchase of R&D services in biotechnology (thousands of euros): Abroad;45.664;5.054;50.718;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;47;23;45;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;12;13;12;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;16;15;16;
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;13;15;14;
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;17;11;16;
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;19;10;18;
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;16;13;15;
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;37;29;37;
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;53;39;52;
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;20;14;20;
% Companies that have requested biotechnology patents in Biotechnology;15;17;15;
Number of patents requested;525;156;681;
% Companies with income of an international origin related to biotechnological activities;24,9;18,4;24,3;
% Turnover representing income of an international origin related to biotechnological activities;6;1;1;
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;45,2;73,1;59,6;
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;54,8;26,9;40,4;
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;89;72,5;80,4;
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;7,5;24,9;16,5;
% Income of an international origin related with activities according to the classification: Operating source abroad;2,2;2,3;2,2;
% Income of an international origin related with activities according to the classification: Other;1,4;0,4;0,9;
Notas:
'.'=numeric piece of data equal to zero not resulting from rounding 

 FTE: Full Time Equivalent
Fuente: National Statistics Institute